Role of Sp1 expression in gastric cancer: A meta‑analysis and bioinformatics analysis

Shi,Shuai; Zhang,Zhi‑Gang

doi:10.3892/ol.2019.10775

Role of Sp1 expression in gastric cancer: A meta‑analysis and bioinformatics analysis

Authors:
- Shuai Shi
- Zhi‑Gang Zhang
View Affiliations

Affiliations: Department of Pathology, Cangzhou People's Hospital, Cangzhou, Hebei 061000, P.R China
Published online on: August 22, 2019 https://doi.org/10.3892/ol.2019.10775
Pages: 4126-4135
Copyright: © Shi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sp1 (specificity protein 1) is an important transcription factor that regulates multiple cancer‑related genes. A number of published studies have explored the relationship between Sp1 expression and prognosis in gastric cancer. Therefore, a deeper level of understanding is required into the molecular biological mechanism of gastric cancer. Finding new tumor biomarkers for the accurate prediction of occurrence, recurrence and metastasis of gastric cancer are of great significance. The present study uses a systematic meta‑analysis and bioinformatics analysis to acquire evidence for a prognosis marker based on Sp1 expression in gastric cancer. A literature search was performed using PubMed and China National Knowledge Infrastructure on 8th June, 2018. A total of 13 studies were included in the meta‑analysis. The meta‑analysis showed that the expression of Sp1 was significantly higher in gastric cancer tissue, compared with that of normal mucosa [odds ratio (OR), ‑0.53; 95% CI, ‑0.62‑0.44; P<0.0001] and dysplasia (OR, 0.24; 95% CI, 0.13‑0.44; P<0.0001). A positive association was found Sp1 expression and depth of invasion (OR, 0.31; 95% CI, 0.11‑0.86), lymph node metastasis (OR, 0.36; 95% CI, 0.22‑0.59), TNM staging of gastric cancer (OR, 0.43; 95% CI, 0.24‑0.79) and Lauren's classification (OR, 0.83; 95% CI, 0.51‑1.36), but not with sex or tumor differentiation (OR, 1.34; 95% CI, 0.95‑1.88). According to the Oncomine database, Sp1 mRNA expression is significantly higher in gastric cancer tissues compared with that in normal tissues (P<0.05), including that of intestinal, diffuse and mixed‑type gastric carcinomas (P<0.05). Kaplan‑Meier plots show that the expression of Sp1 mRNA is negatively associated with overall and progression‑free survival rates of patients with gastric cancer, even when stratified according to expression level (P<0.05). The selected prediction parameter is overall survival or progressive‑free survival rate. The expression level of Sp1 was divided into high expression group and low expression group according to the best cut off value provided on the Kaplan‑Meier plotter. However, Sp1 protein expression is upregulated in gastric cancer tissues compared with normal tissues and is positively associated with depth of invasion and TNM stage of gastric cancer. The high protein expression of Sp1 might make it a good potential marker for the prognosis of patients with gastric cancer.

View Figures

View References

1	Kadonaga JT, Carner KR, Masiarz FR and Tjian R: Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell. 51:1079–1090. 1987. View Article : Google Scholar : PubMed/NCBI
2	Roder K, Kim KH and Sul HS: Induction of murine H-rev107 gene expression by growth arrest and histone acetylation: Involvement of an Sp1/Sp3-binding GC-box. Biochem Biophys Res Commun. 294:63–70. 2002. View Article : Google Scholar : PubMed/NCBI
3	Samson SL and Wong NC: Role of Sp1 in insulin regulation of gene expression. J Mol Endocrinol. 29:265–279. 2002. View Article : Google Scholar : PubMed/NCBI
4	Safe S and Abdelrahim M: Sp transcription factor family and its role in cancer. Eur J Cancer. 41:2438–2448. 2005. View Article : Google Scholar : PubMed/NCBI
5	Zaid A, Li R, Luciakova K, Barath P, Nery S and Nelson BD: On the role of the general transcription factor Sp1 in the activation and repression of diverse mammalian oxidative phosphorylation genes. J Bioenerg Biomembr. 31:129–135. 1999. View Article : Google Scholar : PubMed/NCBI
6	Duan H, Heckman CA and Linda MB: Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol. 25:1608–1619. 2005. View Article : Google Scholar : PubMed/NCBI
7	Wu J, Ling X, Pan D, Apontes P, Song L, Liang P, Altieri DC, Beerman T and Li F: Molecular mechanism of inhibition of survivin transcription by the GC-rich sequence-selective DNA binding antitumor agent, hedamycin: Evidence of survivin down-regulation associated with drug sensitivity. J Biol Chem. 280:9745–9751. 2005. View Article : Google Scholar : PubMed/NCBI
8	Martin M, Le J and Delanlan S: TGF-beta1 and radiation fibrosis: A master switch and a specific therapeutic target? Int J Rad Oncol Biol Phys. 47:277–290. 2000. View Article : Google Scholar
9	Jungert K, Buck A, Buchholz M, Wagner M, Adler G, Gress TM and Ellenrieder V: Smad-Sp1 complexes mediate TGFbeta-induced early transcription of oncogenic Smad7 in pancreatic cancer cells. Carcinogenesis. 27:2392–2401. 2006. View Article : Google Scholar : PubMed/NCBI
10	Wang S, Wang W, Wesley RA and Danner RL: A Sp1 binding site of the tumor necrosis factor alpha promoter functions as a nitric oxide response element. J Biol Chem. 274:33190–33193. 1999. View Article : Google Scholar : PubMed/NCBI
11	Chae YS, Kim JG, Sohn SK, Cho YY, Moon JH, Bae HI, Park JY, Lee MH, Lee HC, Chung HY and Yu W: Investigation of vascular endothelial growth factor gene polymorphisms and its association with clinicopathologic characteristics in gastric cancer. Oncology. 71:266–272. 2006. View Article : Google Scholar : PubMed/NCBI
12	Yao JC, Wang L, Wei D, Gong W, Hassan M, Wu TT, Mansfield P, Ajani J and Xie K: Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res. 15:4109–4117. 2004. View Article : Google Scholar
13	Maurer GD, Leupold JH, Schewe DM, Biller T, Kates RE, Hornung HM, Lau-Werner U, Post S and Allgayer H: Analysis of specific transcriptional regulators as early predictors of independent prognostic relevance in resected colorectal cancer. Clinic Cancer Res. 13:1123–1132. 2007. View Article : Google Scholar
14	Chen QN, Yuan P and Fan YZ: Expression of transcription factor Sp1 in pancreatic cancer and its relationship with prognosis. J Tongji Univ. 30:5–8. 2009.
15	Zhang W, Kadam S, Emerson BM and Bieker JJ: Site-specific acetylation by p300 or CREB binding protein regulates erythroid Krüppel-like factor transcriptional activity via its interaction with the SWI-SNF complex. Mol Cell Biol. 21:2413–2422. 2001. View Article : Google Scholar : PubMed/NCBI
16	Chiefari E, Brunetti A, Arturi F, Bidart JM, Russo D, Schlumberger M and Filetti S: Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: A role in NIS expression regulation? BMC Cancer. 2:352002. View Article : Google Scholar : PubMed/NCBI
17	Hosoi Y, Watanabe T, Nakagawa K, Matsumoto Y, Enomoto A, Morita A, Nagawa H and Suzuki N: Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer. Int J Oncol. 25:461–468. 2004.PubMed/NCBI
18	Maor S, Mayer D, Yarden RI, Lee AV, Sarfstein R, Werner H and Papa MZ: Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: Involvement of transcription factor Sp1. J Endocrinol. 191:605–612. 2006. View Article : Google Scholar : PubMed/NCBI
19	Han WD, Mu YM, Lu XC, Xu ZM, Li XJ, Yu L, Song HJ, Li M, Lu JM, Zhao YL and Pan CY: Up-regulation of LRP16 mRNA by 17beta-estradiol through activation of estrogen receptor alpha (ERalpha), but not ERbeta, and promotion of human breast cancer MCF-7 cell proliferation: A preliminary report. Endocr Relat Cancer. 10:217–224. 2003. View Article : Google Scholar : PubMed/NCBI
20	Marin M, Karis A, Visser P, Grosveld F and Philipsen S: Transcription factor Sp1 is essential for early embryonic development but dispensable for cell growth and differentiation. Cell. 89:619–628. 1997. View Article : Google Scholar : PubMed/NCBI
21	Liu DC, Liang Q, Tao T, Huang YQ, Xu B, Chen NG, Zhang ZG, Dong Y, Han CH and Chen M: Sp1 promotes cell metabolism and proliferation through PKM2 pathway in prostate cancer. J Southeast Univ (Med Sci Edi). 10:337–341. 2015.
22	Beaver LM, Buchanan A, Sokolowski EI, Riscoe AN, Wong CP, Chang JH, Löhr CV, Williams DE, Dashwood RH and Ho E: Transcriptome analysis reveals a dynamic and differential transcriptional response to sulforaphane in normal and prostate cancer cells and suggests a role for Sp1 in chemoprevention. Mol Nutr Food Res. 58:2001–2013. 2014. View Article : Google Scholar : PubMed/NCBI
23	Hao C and Meng A: Sp1-like transcription factors are regulators of embryonic development in vertebrates. Dev Growth Differ. 47:201–211. 2005. View Article : Google Scholar : PubMed/NCBI
24	Homas K, Wu J, Sung DY, Thompson W, Powell M, McCarrey J, Gibbs R and Walker W: SP1 transcription factors in male germ cell development and differentiation. Mol Cell Endocrinol. 270:1–7. 2007. View Article : Google Scholar : PubMed/NCBI
25	Wei YZ, Li CF and Xue YW: Expression of transcription factor SP1, vascular endothelial growth factor and CD34 in serosa-infiltrating gastric cancer and their relationship with biological behavior and prognosis. Zhonghua Wei Chang Wai Ke Za Zhi. 12:145–149. 2009.(In Chinese). PubMed/NCBI
26	Wang LW, Wei D, Huang S, Peng Z, Le X, Wu TT, Yao J, Ajani J and Xie K: Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res. 9:6371–6380. 2003.PubMed/NCBI
27	Hua ZL, Zhu YC, Guo GP, Ling RB, Zhou Q and Shi AW: Expression of transcription factors in gastric cancer and its relationship with clinical pathology. Med Imaging. 9:162–163. 2013.
28	Zhang J, Zhu ZG, Ji J, Yuan F, Yu YY, Liu BY and Lin YZ: Transcription factor Sp1 expression in gastric cancer and its relationship to long-term prognosis. World J Gastroenterol. 11:2213–2217. 2005. View Article : Google Scholar : PubMed/NCBI
29	Zhang PC, Liang L, Zhang DK, Yao BH, Song L, Li Y and Zhao JS: Expression and significance of transcription factor Sp1 and Stat-3 in gastric carcinoma. Chin J Gen Surg. 23:1714–1716. 2014.
30	Zhang RR: Expression of correlation relationship and significance of Sp1, Notch1 and KLF4 in gastric cancer. Msater Thesis, Shanxi Med Univ China. 2011.
31	A JD: The clinical study on expression and significance of Sp1 protein in gastric carcinoma. Master Thesis, Qinghai Univ China. 2011.
32	Zhu HH, Wu XM and Ye CJ: Expression of matrix metalloproteinase-11 and the transcription factor Sp1 in gastric cancer. J Qinghai Med College. 36:49–53. 2015.
33	Jiang MZ: Study about the expression and significance of KLF5, Sp1 and CyclinD1 in carcinoma of stomach. Kunming. Msater Thesis, Med Univ China. 2009.
34	Jiang W, Jin Z, Zhou F, Cui J and Wang L and Wang L: High co-expression of Sp1 and HER-2 is correlated with poor prognosis of gastric cancer patients. Surg Oncol. 24:220–225. 2015. View Article : Google Scholar : PubMed/NCBI
35	Cui JF, Zhao CY, Cao LY, Wu WN, Li YH, Wang Y, Xue LY and Zhang XG: Comparison of KLF4, SP1, and Cyclin D1 expressions between ad-enocarcinanoma of the esophagogastric junction and distal gastric adenocarcinoma. Chin J Clin Oncol. 41:108–112. 2014.
36	Lee HS, Park CK, Oh E, Erkin ÖC, Jung HS, Cho MH, Kwon MJ, Chae SW, Kim SH, Wang LH, et al: Low SP1 expression differentially affects intestinal-type compared with diffuse-type gastric adenocarcinoma. PLoS One. 8:e555222013. View Article : Google Scholar : PubMed/NCBI
37	Kumar AP and Butler AP: Serum responsive gene expression mediated by Sp1. Biochem Biophys Res Commun. 252:517–523. 1998. View Article : Google Scholar : PubMed/NCBI
38	Chen F, Zhang F, Rao J and Studzinski GP: Ectopic expression of truncated Sp1 transcription factor prolongs the S phase and reduces the growth rate. Anticancer Res. 20:661–667. 2000.PubMed/NCBI
39	Peng H, Li Y, Liu Y, Zhang J, Chen K, Huang A and Tang H: HBx and SP1 upregulate DKK1 expression. Acta Biochim Pol. 64:35–39. 2017.PubMed/NCBI
40	Yu MH and Zhang W: TEAD1 enhances proliferation via activating SP1 in colorectal cancer. Biomed Pharmacother. 83:496–501. 2016. View Article : Google Scholar : PubMed/NCBI
41	Shi H, Li Y, Feng G, Li L, Fang R, Wang Z, Qu J, Ding P, Zhang X and Ye L: The oncoprotein HBXIP up-regulates FGF4 through activating transcriptional factor Sp1 to promote the migration of breast cancer cells. Biochem Biophys Res Commun. 471:89–94. 2016. View Article : Google Scholar : PubMed/NCBI
42	Milanini-Mongiat J, Pouysségur J and Pagès G: Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases. Their implication in vascular endothelial growth factor gene transcription. J Biol Chem. 277:20631–20639. 2002. View Article : Google Scholar : PubMed/NCBI
43	Merchant JL, Du M and Todisco A: Sp1 phosphorylation by Erk 2 stimulates DNA binding. Biochem Biophys Res Commun. 254:454–461. 1999. View Article : Google Scholar : PubMed/NCBI
44	Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL and Xie K: Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res. 64:2030–2038. 2004. View Article : Google Scholar : PubMed/NCBI
45	Zhao S, Venkatasubbarao K, Li S and Freeman JW: Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells. Cancer Res. 63:2624–2630. 2003.PubMed/NCBI
46	Suske G: The Sp-family of transcription factors. Gene. 238:291–300. 1999. View Article : Google Scholar : PubMed/NCBI
47	Wright C, Angus B, Napier J, Wetherall M, Udagawa Y, Sainsbury JR, Johnston S, Carpenter F and Horne CH: Prognostic factors in breast cancer: Immunohistochemical staining for SP1 and NCRC 11 related to survival, tumour epidermal growth factor receptor and oestrogen receptor status. J Pathol. 153:325–331. 1987. View Article : Google Scholar : PubMed/NCBI
48	Shi Q, Le X, Abbruzzese JL, Peng Z, Qian CN, Tang H, Xiong Q, Wang B, Li XC and Xie K: Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res. 61:4143–4154. 2001.PubMed/NCBI
49	Zhang J, Jiang RX, Fan XM, Lou L, Liu WN, Zhao XW and Li YH: Expression and prognostic significance of Sp1. Klf4 and p21 in the ovary serous adenocarcinoma. J Clin Exp Pathol. 33:22–26. 2017.
50	Liu CF, Ji YC, Sun YY and Li XD: Expression of SP1 in colorectal cancer and its relation ship with biological behavior and prognosis. Chin J Gastroenterol Hepatol. 20:51–53. 2011.
51	Wang XB, Peng WQ, Yi ZJ, Zhu SL and Gan QH: Expression and prognostic value of transcriptional factor sp1 in breast cancer. Ai Zheng. 26:996–1000. 2007.(In Chinese). PubMed/NCBI
52	Pan Q, Zhu K, Chen WY, Zhang JB, Sun HC, Wang L and Ren N: Correlation of transcription factor Sp1 expression with clinical and pathological characteristics and prognosis of hepatocellular carcinoma. Chin J Clin Oncol. 41:1284–1287. 2014.
53	Chen QN, Yuan P, Fan YZ, et al: Expression of transcription factor Sp1 in human pancreatic ductal carcinoma and its relationship with prognosis. J Tongji Univ (Med Sci). 30:5–8. 2009.